Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2012
At a glance
- Drugs Bortezomib (Primary) ; Thalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Jun 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 01 Jun 2012 Results published in the European Journal of Haematology.
- 08 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History